Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms.
- Author:
Qi SONG
;
Xiaoming LI
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
Carcinoma, Squamous Cell;
drug therapy;
Drug Resistance, Neoplasm;
ErbB Receptors;
Head and Neck Neoplasms;
drug therapy;
Humans;
Signal Transduction;
Squamous Cell Carcinoma of Head and Neck
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2015;29(2):184-190
- CountryChina
- Language:Chinese
-
Abstract:
Overexpression of the epidermal growth factor receptor (EGFR) is a common characteristic of head and neck squamous cell carcinomas (HNSCC) , and initiates important signal transduction pathways in carcinogenesis. Now the EGFR is a validated target for cancer therapies in HNSCC. However, the effect of EGFR-targeted therapies is only modest because of primary and/or acquired resistance. Therefore, an improved understanding of the molecular mechanisms of resistance to EGFR inhibitors may establish new treatment options to overcome resistance. In this review, the molecular mechanisms of resistance and the strategies to overcome it were summarized.
